| Literature DB >> 28900743 |
Sri Pragnya Cheruku1, Grandhi Venkata Ramalingayya1, Mallikarjuna Rao Chamallamudi1, Subhankar Biswas1, Krishnadas Nandakumar1, Madhavan Nampoothiri1, Karthik Gourishetti1, Nitesh Kumar2.
Abstract
Cognitive dysfunction by chemotherapy compromises the quality of life in cancer patients. Tea polyphenols are known chemopreventive agents. The present study was designed to evaluate the neuroprotective potential of (+) catechin hydrate (catechin), a tea polyphenol, in IMR-32 neuroblastoma cells in vitro and alleviation of episodic memory deficit in Wistar rats in vivo against a widely used chemotherapeutic agent, Doxorubicin (DOX). In vitro, neuroprotective studies were assessed in undifferentiated IMR-32 cells using percentage viability and in differentiated cells by neurite length. These studies showed catechin increased percentage viability of undifferentiated IMR-32 cells. Catechin pretreatment also showed an increase in neurite length of differentiated cells. In vivo neuroprotection of catechin was evaluated using novel object recognition task in time-induced memory deficit model at 50, 100 and 200 mg/kg dose and DOX-induced memory deficit models at 100 mg/kg dose. The latter model was developed by injection of DOX (2.5 mg/kg, i.p.) in 10 cycles over 50 days in Wistar rats. Catechin showed a significant reversal of time-induced memory deficit in a dose-dependent manner and prevention of DOX-induced memory deficit at 100 mg/kg. In addition, catechin treatment showed a significant decrease in oxidative stress, acetylcholine esterase and neuroinflammation in the hippocampus and cerebral cortex in DOX-induced toxicity model. Hence, catechin may be a potential adjuvant therapy for the amelioration of DOX-induced cognitive impairment which may improve the quality of life of cancer survivors. This improvement might be due to the elevation of antioxidant defense, prevention of neuroinflammation and inhibition of acetylcholine esterase enzyme.Entities:
Keywords: (+) Catechin hydrate; Chemobrain; Doxorubicin; Episodic memory; IMR-32 cells; Neuroprotection
Year: 2017 PMID: 28900743 PMCID: PMC5809655 DOI: 10.1007/s10616-017-0138-8
Source DB: PubMed Journal: Cytotechnology ISSN: 0920-9069 Impact factor: 2.058